Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Sheaff Brock Investment Advisors LLC

Sheaff Brock Investment Advisors LLC increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 8.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 7,747 shares of the biopharmaceutical company’s stock after buying an additional 629 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Halozyme Therapeutics were worth $370,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. RPg Family Wealth Advisory LLC acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at about $1,886,000. Segall Bryant & Hamill LLC boosted its holdings in shares of Halozyme Therapeutics by 16.3% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock valued at $20,330,000 after buying an additional 49,856 shares during the period. Retirement Systems of Alabama boosted its holdings in shares of Halozyme Therapeutics by 23.5% in the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock valued at $22,282,000 after buying an additional 74,173 shares during the period. South Street Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at about $9,812,000. Finally, Foster & Motley Inc. boosted its holdings in shares of Halozyme Therapeutics by 118.6% in the 4th quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company’s stock valued at $1,113,000 after buying an additional 12,630 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Down 0.5 %

HALO stock opened at $58.29 on Monday. Halozyme Therapeutics, Inc. has a 52 week low of $35.23 and a 52 week high of $65.53. The company has a market capitalization of $7.42 billion, a price-to-earnings ratio of 19.30, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. The firm’s 50-day moving average is $52.50 and its two-hundred day moving average is $54.49. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32.

Insiders Place Their Bets

In related news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the sale, the director now directly owns 38,611 shares in the company, valued at $2,173,799.30. The trade was a 11.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.40% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of Halozyme Therapeutics in a report on Tuesday, February 4th. Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. JMP Securities boosted their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Finally, Wells Fargo & Company reduced their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.89.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.